ADAM8 Antibody (143303) [Unconjugated]

Western blot shows Recombinant Human ADAM8 aa 158-497 (Catalog # 1031-AD). PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human ADAM8 Monoclonal Antibody (Catalog # MAB1031) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for ADAM8 aa158-497 at approximately 40 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

• Reactivity: Hu
• Applications: WB, IP
• Clone: 143303
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

ADAM8 Antibody (143303) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human ADAM8 ectodomain
  Asp158-Ser653
  Accession # P78325
• Specificity: Detects human ADAM8 in direct ELISAs and Western blots. In Western blots, less than 5% cross-reactivity with the ectodomains of recombinant human ADAM9, 10, 15, 17, and 19 is observed. Detects an epitope within aa 201‑497 of recombinant human ADAM8 which corresponds to the metalloprotease and disintegrin-like domains.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: ADAM8
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation 25 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ADAM8 Antibody (143303) [Unconjugated]

• a disintegrin and metalloproteinase domain 8
• ADAM 8
• ADAM metallopeptidase domain 8
• ADAM8
• CD156a antigen
• CD156a
• CD156human leukocyte differentiation antigen
• Cell surface antigen MS2
• EC 3.4.24
• EC 3.4.24.-
• MGC134985
• MS2
• MS2disintegrin and metalloproteinase domain-containing protein 8

Background

ADAM8, also known as cell surface antigen MS2 or CD156a, is a member of the ADAM family that contains a disintegrin and metalloprotease-like domain (1, 2). ADAM8 can cleave a variety of substrates and has been shown as a sheddase for the low affinity IgE receptor CD23 and the neural recognition molecule CHL1 (3, 4). Expression and regulation studies suggest that ADAM8 is a novel osteoclast stimulating factor and may play a role in asthma (5, 6). The 824 amino acid precursor of human ADAM8 consists of a signal peptide (residues 1 to 16), a pro peptide (residues 17 to 199), a metaloprotease domain (residues 200 to 400), a disintegrin-like domain (residues 408 to 494), a cysteine-rich region (residues 497 to 613), an EGF-like domain (residues 614 to 640), a transmembrane region (residues 656 to 676) and a cytoplasmic domain (residues 677 to 824).

1. Yoshiyama, K. et al. (1997) Genomics 41:56.
2. Moss, M.L. and J.W. Bartsch (2004) Biochemistry 43:7227.
3. Fourie, A.M. et al. (2003) J. Biol. Chem. 278:30469.
4. Naus, S. et al. (2004) J. Biol. Chem. 279:16083.
5. Choi, S.J. et al. (2001) J. Bone Miner. Res. 16:814.
6. King, N.E. et al. (2004) Am. J. Respir. Cell Mol. Biol. 31:257.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for ADAM8 Antibody (MAB1031)(3)

Publications using MAB1031

• Mineva, ND;Pianetti, S;Das, SG;Srinivasan, S;Billiald, NM;Sonenshein, GE; A Novel Class of Human ADAM8 Inhibitory Antibodies for Treatment of Triple-Negative Breast Cancer Pharmaceutics 2024-04-13 [PMID: 38675197] (Functional Assay Control, N/A)
• C Conrad, D Yildiz, SJ Cleary, A Margraf, L Cook, U Schlomann, B Panaretou, JL Bowser, H Karmouty-Q, J Li, NK Berg, SC Martin, A Aljohmani, SF Moussavi-H, KM Wang, JJ Tian, M Magnen, C Valet, L Qiu, JP Singer, HK Eltzschig, CAPSys Stu, W Bertrams, S Herold, N Suttorp, B Schmeck, ZT Ball, A Zarbock, MR Looney, JW Bartsch ADAM8 signaling drives neutrophil migration and ARDS severity JCI Insight, 2022-02-08;7(3):. 2/8/2022 [PMID: 35132956]
• Mathilde Romagnoli, Nora D Mineva, Michael Polmear, Catharina Conrad, Srimathi Srinivasan, Delphine Loussouarn et al. ADAM 8 expression in invasive breast cancer promotes tumor dissemination and metastasis EMBO Molecular Medicine 2014-02-01 [PMID: 24375628]

Bioinformatics

• Gene Symbol: ADAM8
• Uniprot:
  • P78325()